Reduction of Intraocular Pressure (IOP): Dorzolamide is a carbonic anhydrase inhibitor that works by decreasing the production of aqueous humor in the eye, thereby lowering intraocular pressure. It is typically used as an adjunctive therapy when monotherapy with beta-blockers or prostaglandin analogs is insufficient to control IOP.
Treatment of Open-Angle Glaucoma: Open-angle glaucoma is a chronic eye condition characterized by increased fluid pressure within the eye, which can damage the optic nerve and lead to vision loss. Dorzolamide, either alone or in combination with other anti-glaucoma medications, is used to manage this condition and prevent further optic nerve damage.
Management of Ocular Hypertension: Ocular hypertension refers to elevated intraocular pressure without signs of optic nerve damage or visual field loss characteristic of glaucoma. Dorzolamide can be prescribed to lower IOP in individuals with ocular hypertension to reduce the risk of developing glaucoma.
Adjunctive Therapy: Dorzolamide is often prescribed in combination with other intraocular pressure-lowering medications, such as beta-blockers (e.g., timolol) or prostaglandin analogs (e.g., latanoprost), to achieve optimal IOP control. Combination therapy may offer additive or synergistic effects in reducing IOP.
Improved Ocular Blood Flow: Some studies suggest that dorzolamide may have vasodilatory effects on ocular blood vessels, potentially improving ocular perfusion and blood flow to the retina and optic nerve head. This may contribute to its neuroprotective properties in glaucoma management.
Decreased Risk of Visual Field Loss: By effectively lowering intraocular pressure, dorzolamide helps reduce the risk of progressive visual field loss and deterioration of visual function associated with glaucoma. Early initiation and consistent use of dorzolamide therapy may help preserve vision in affected individuals.
Enhanced Outflow Facility: Dorzolamide may enhance aqueous outflow through the trabecular meshwork, facilitating the drainage of intraocular fluid from the eye. This mechanism of action contributes to its ability to reduce intraocular pressure and improve ocular hemodynamics.
Adjunctive Therapy in Pediatric Glaucoma: Dorzolamide can be used as adjunctive therapy in children and adolescents with pediatric glaucoma to lower intraocular pressure and prevent optic nerve damage. It is often administered in combination with other topical anti-glaucoma medications.
Bacteria Impacted by dorzolamide hydrochloride,(prescription)
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
Impact of dorzolamide hydrochloride,(prescription) on Conditions from US National Library of Medicine
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups.
We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio: Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
This is an Academic site. It generates
theoretical models
of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some
hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [216.73.216 ]
